Dr. Nayak graduated with a medical degree in 1982 from the Maulana Azad Medical College Delhi University, followed by Internal Medicine Residency at Coney Island Hospital, SUNY, Brooklyn NY. In 1999, Dr. Nayak was awarded the Hematology Fellowship at Coney Island Hospital, SUNY Brooklyn, NY and the Oncology Fellowship with Augusta University in 2002. Currently Dr. Nayak is an Assistant Professor of Medicine, Department of Hematology / Oncology Department, Augusta University. Dr. Nayak is certified by the American Board of Internal Medicine in Hematology and Oncology Specialties.
Dr. Nayak is currently a member of several committees, including Onyx and Bayer Speaker Bureau for Nexavar, MCG Cancer Center Molecular Oncology Programme, and MCG Cancer Center Gastrointestinal Tumor Board Committee.
Abstracts that Dr. Nayak has participated: Incidence of Red Cell auto-antibodies in Hepatitis C Patients; An Unusual Case of Large Cell Lymphoma in Patients with AIDS.; and Role of Radiochemotherapy in Advanced Biliary Cancers. Publications for Dr. Nayak include: Hepatic Failure caused by Plasma Cell Infiltration in Multiple Myeloma, and Plasmablastic Lymphoma with Small Lymphocytic Lymphoma: Clinicopathologic Features, and Review of the Literature.
Areas of Expertise (3)
- Onyx and Bayer Speaker Bureau for Nexavar : Member
- MCG Cancer Center Molecular Oncology Programme : Member
- MCG Cancer Center Gastrointestinal Tumor Board Committee : Member
Media Appearances (1)
Second Opinion Gives Cancer Patient a New Lease on Life!!
Medisense Health online
Edwards began receiving treatment at the Georgia Cancer Center in July and was placed under the care of Dr. Asha Nayak-Kapoor, associate professor in the Division of Hematology and Oncology, and Dr. Stephen Ramey, assistant professor in the Department of Radiation Oncology in the Medical College of Georgia.
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid TumorsClinical Cancer Research
The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolumab in patients with locally advanced or metastatic solid tumors.
Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In VivoCancers
A key feature of human colorectal tumor is loss of FAS expression. FAS is the death receptor for FASL of activated T cells. Loss of FAS expression therefore may promote tumor cell immune escape. We aimed at determining whether restoring FAS expression is sufficient to suppress colorectal tumor growth.
Autocrine IL6-Mediated Activation of the STAT3–DNMT Axis Silences the TNFα–RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor CellsCancer Research
Although accumulation of myeloid-derived suppressor cells (MDSC) is a hallmark of cancer, the underlying mechanism of this accumulation within the tumor microenvironment remains incompletely understood. We report here that TNFα–RIP1–mediated necroptosis regulates accumulation of MDSCs.